image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 11.82
-5.14 %
$ 478 M
Market Cap
-2.11
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one ANGO stock under the worst case scenario is HIDDEN Compared to the current market price of 11.8 USD, AngioDynamics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one ANGO stock under the base case scenario is HIDDEN Compared to the current market price of 11.8 USD, AngioDynamics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one ANGO stock under the best case scenario is HIDDEN Compared to the current market price of 11.8 USD, AngioDynamics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
304 M REVENUE
-10.28%
-192 M OPERATING INCOME
-900.55%
-184 M NET INCOME
-251.53%
-28.2 M OPERATING CASH FLOW
-36100.00%
124 M INVESTING CASH FLOW
1369.41%
-64.2 M FINANCING CASH FLOW
-252.75%
72.8 M REVENUE
7.93%
-2.51 M OPERATING INCOME
80.85%
-10.7 M NET INCOME
16.10%
2.47 M OPERATING CASH FLOW
113.55%
-1.96 M INVESTING CASH FLOW
18.46%
-1.12 M FINANCING CASH FLOW
-120.63%
Balance Sheet AngioDynamics, Inc.
image
Current Assets 193 M
Cash & Short-Term Investments 76.1 M
Receivables 43.6 M
Other Current Assets 73.6 M
Non-Current Assets 124 M
Long-Term Investments 0
PP&E 41.5 M
Other Non-Current Assets 82.9 M
Current Liabilities 91.2 M
Accounts Payable 37.8 M
Short-Term Debt 1.98 M
Other Current Liabilities 51.4 M
Non-Current Liabilities 20.9 M
Long-Term Debt 3.94 M
Other Non-Current Liabilities 17 M
EFFICIENCY
Earnings Waterfall AngioDynamics, Inc.
image
Revenue 304 M
Cost Of Revenue 149 M
Gross Profit 155 M
Operating Expenses 347 M
Operating Income -192 M
Other Expenses -8.09 M
Net Income -184 M
RATIOS
50.90% GROSS MARGIN
50.90%
-63.32% OPERATING MARGIN
-63.32%
-60.66% NET MARGIN
-60.66%
-89.67% ROE
-89.67%
-58.03% ROA
-58.03%
-81.02% ROIC
-81.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AngioDynamics, Inc.
image
Net Income -184 M
Depreciation & Amortization 27.7 M
Capital Expenditures -5.77 M
Stock-Based Compensation 10.5 M
Change in Working Capital 14.4 M
Others 99.9 M
Free Cash Flow -33.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AngioDynamics, Inc.
image
Wall Street analysts predict an average 1-year price target for ANGO of $12.7 , with forecasts ranging from a low of $12 to a high of $14 .
ANGO Lowest Price Target Wall Street Target
12 USD 1.52%
ANGO Average Price Target Wall Street Target
12.7 USD 7.16%
ANGO Highest Price Target Wall Street Target
14 USD 18.44%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership AngioDynamics, Inc.
image
Sold
0-3 MONTHS
50 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
136 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
67 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Jan 16, 2025
Sell 50 K USD
Nighan Warren JR
SVP Quality and Regulatory
- 4060
12.31 USD
3 months ago
Oct 10, 2024
Bought 608 USD
Nighan Warren JR
SVP Quality and Regulatory
+ 100
6.08 USD
3 months ago
Oct 07, 2024
Bought 4.68 K USD
Nighan Warren JR
SVP Quality and Regulatory
+ 768
6.09 USD
3 months ago
Oct 08, 2024
Bought 9.96 K USD
Trowbridge Stephen A
EVP and CFO
+ 1700
5.86 USD
3 months ago
Oct 07, 2024
Bought 121 K USD
Clemmer James C
President and CEO
+ 20000
6.03 USD
9 months ago
Apr 08, 2024
Bought 67 K USD
Clemmer James C
President and CEO
+ 10000
6.7 USD
2 years ago
Jan 31, 2023
Sell 60 K USD
Helsel Dave
SVP Global Operations and R&D
- 4633
12.95 USD
2 years ago
Oct 12, 2022
Bought 15 K USD
Trowbridge Stephen A
EVP and CFO
+ 1083
13.82 USD
2 years ago
Oct 10, 2022
Bought 150 K USD
Clemmer James C
President and CEO
+ 10000
15 USD
2 years ago
Jul 29, 2022
Sell 112 K USD
Helsel Dave
SVP Global Operations and R&D
- 5000
22.44 USD
2 years ago
Apr 28, 2022
Sell 78.8 K USD
Helsel Dave
SVP Global Operations and R&D
- 3513
22.44 USD
2 years ago
Apr 11, 2022
Sell 143 K USD
JOHNSON WESLEY
Director
- 6201
23 USD
2 years ago
Apr 11, 2022
Sell 30.2 K USD
JOHNSON WESLEY
director:
- 1299
23.26 USD
3 years ago
Jan 12, 2022
Bought 22.6 K USD
Trowbridge Stephen A
EVP and CFO
+ 1000
22.64 USD
3 years ago
Jan 11, 2022
Bought 228 K USD
Clemmer James C
President and CEO
+ 10000
22.84 USD
3 years ago
Oct 20, 2021
Sell 97.7 K USD
Helsel Dave
SVP Global Operations and R&D
- 3494
27.97 USD
3 years ago
Oct 15, 2021
Sell 335 K USD
Centea Scott
Sr. VP/GM, Global VIT
- 12000
27.92 USD
3 years ago
Oct 05, 2021
Sell 292 K USD
Campbell Chad Thomas
SVP/GM, Vascular Access
- 10748
27.15 USD
3 years ago
Apr 14, 2021
Sell 83.8 K USD
Helsel Dave
SVP Global Operations and R&D
- 3500
23.93 USD
4 years ago
Jan 20, 2021
Sell 120 K USD
JOHNSON WESLEY
Director
- 6500
18.53 USD
4 years ago
Aug 11, 2020
Bought 9.5 K USD
Trowbridge Stephen A
EVP and CFO
+ 1013
9.38 USD
4 years ago
Jul 31, 2020
Bought 330 K USD
Clemmer James C
President and CEO
+ 40000
8.26 USD
5 years ago
Oct 25, 2019
Bought 213 K USD
Clemmer James C
President and CEO
+ 15000
14.19 USD
5 years ago
Jul 16, 2019
Sell 293 K USD
Gould Kevin J
Director
- 13650
21.45 USD
6 years ago
Nov 07, 2018
Sell 41.7 K USD
Greiner Michael
EVP and CFO
- 1939
21.53 USD
7 years ago
Nov 15, 2017
Sell 446 K USD
Richard Stark
SVP, GM - Oncology
- 27409
16.29 USD
7 years ago
Jul 24, 2017
Bought 5.06 K USD
REED JAN STERN
Director
+ 316
16 USD
7 years ago
Jul 21, 2017
Bought 78.6 K USD
DONNELLY HOWARD W
Director
+ 5000
15.72 USD
7 years ago
Jul 21, 2017
Bought 79 K USD
Clemmer James C
President and CEO
+ 5000
15.79 USD
7 years ago
Jul 20, 2017
Bought 313 K USD
Clemmer James C
President and CEO
+ 20000
15.64 USD
7 years ago
Apr 12, 2017
Sell 23.3 M USD
Burgstahler David F
director, 10 percent owner:
- 1456947
16 USD
7 years ago
Apr 12, 2017
Sell 8.14 M USD
Burgstahler David F
director, 10 percent owner:
- 508869
16 USD
7 years ago
Apr 12, 2017
Sell 6.15 M USD
Burgstahler David F
director, 10 percent owner:
- 384184
16 USD
7 years ago
Apr 12, 2017
Sell 23.3 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 1456947
16 USD
7 years ago
Apr 12, 2017
Sell 8.14 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 508869
16 USD
7 years ago
Apr 12, 2017
Sell 6.15 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 384184
16 USD
8 years ago
Nov 18, 2016
Sell 24.3 M USD
Burgstahler David F
director, 10 percent owner:
- 1549945
15.68 USD
8 years ago
Nov 18, 2016
Sell 8.49 M USD
Burgstahler David F
director, 10 percent owner:
- 541349
15.68 USD
8 years ago
Nov 18, 2016
Sell 24.3 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 1549945
15.68 USD
8 years ago
Nov 18, 2016
Sell 8.49 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 541349
15.68 USD
8 years ago
Aug 05, 2016
Sell 20.4 M USD
Burgstahler David F
director, 10 percent owner:
- 1394950
14.62 USD
8 years ago
Aug 05, 2016
Sell 7.12 M USD
Burgstahler David F
director, 10 percent owner:
- 487214
14.62 USD
8 years ago
Aug 05, 2016
Sell 5.38 M USD
Burgstahler David F
director, 10 percent owner:
- 367836
14.62 USD
8 years ago
Aug 05, 2016
Sell 20.4 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 1394950
14.62 USD
8 years ago
Aug 05, 2016
Sell 6.99 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 478214
14.62 USD
8 years ago
Aug 05, 2016
Sell 5.38 M USD
Avista Capital Partners GP, LLC
10 percent owner
- 367836
14.62 USD
8 years ago
May 06, 2016
Sell 43.2 K USD
Greiner Charles R
VP - Global Franchise
- 3508
12.31 USD
8 years ago
Apr 21, 2016
Sell 129 K USD
Trowbridge Stephen A
SVP and General Counsel
- 10500
12.33 USD
8 years ago
Apr 25, 2016
Sell 29.7 K USD
Trowbridge Stephen A
SVP and General Counsel
- 2440
12.18 USD
9 years ago
Feb 13, 2015
Sell 335 K USD
Richard Stark
SVP, GM - Oncology
- 18100
18.53 USD
10 years ago
Oct 20, 2014
Sell 51.5 K USD
Greiner Charles R
VP - Global Franchise
- 3298
15.63 USD
10 years ago
Apr 14, 2014
Bought 13.9 K USD
Kapusta Matthew C
SVP, Business Development
+ 1000
13.9 USD
11 years ago
Nov 13, 2013
Sell 36.8 K USD
Greiner Charles R
VP - Global Finance
- 2392
15.402 USD
11 years ago
Nov 14, 2013
Sell 67.6 K USD
Greiner Charles R
VP - Global Finance
- 4373
15.461 USD
11 years ago
Oct 18, 2013
Bought 76 K USD
BUCCI VINCENT
Director
+ 5000
15.198 USD
11 years ago
Oct 17, 2013
Sell 301 K USD
DONNELLY HOWARD W
Director
- 20000
15.06 USD
11 years ago
Jul 22, 2013
Bought 32.4 K USD
Gould Kevin J
Director
+ 2700
12 USD
11 years ago
May 09, 2013
Sell 15.5 K USD
Greiner Charles R
VP - Global Franchise
- 1495
10.38 USD
11 years ago
Mar 12, 2013
Bought 431 K USD
BUCCI VINCENT
Director
+ 40000
10.78 USD
11 years ago
Mar 12, 2013
Bought 377 K USD
BUCCI VINCENT
Director
+ 35000
10.76 USD
11 years ago
Mar 12, 2013
Bought 108 K USD
BUCCI VINCENT
Director
+ 10000
10.8 USD
11 years ago
Mar 12, 2013
Bought 49.8 K USD
Meteny Dennis S
Director
+ 4600
10.82 USD
11 years ago
Feb 14, 2013
Bought 24.3 K USD
BUCCI VINCENT
Director
+ 2000
12.166 USD
12 years ago
Jan 11, 2013
Bought 31.3 K USD
Gould Kevin J
Director
+ 2700
11.584 USD
12 years ago
Nov 05, 2012
Bought 10.6 K USD
GOLD JEFFREY
Director
+ 1000
10.56 USD
12 years ago
Nov 05, 2012
Sell 32.7 K USD
Richard Stark
SVP, GM - Oncology
- 3160
10.36 USD
12 years ago
Jul 17, 2012
Bought 23.3 K USD
DEVIVO JOSEPH
President and CEO
+ 2000
11.67 USD
12 years ago
May 16, 2012
Sell 25.8 K USD
Richard Stark
SVP, GM - Oncology
- 2080
12.417 USD
12 years ago
Apr 12, 2012
Bought 23.7 K USD
BUCCI VINCENT
Director
+ 2000
11.8674 USD
12 years ago
Apr 12, 2012
Bought 47.3 K USD
BUCCI VINCENT
Director
+ 4000
11.82 USD
12 years ago
Apr 11, 2012
Bought 31.6 K USD
Gould Kevin J
Director
+ 2700
11.717 USD
12 years ago
Apr 09, 2012
Bought 59.1 K USD
DEVIVO JOSEPH
President and CEO
+ 5000
11.8188 USD
12 years ago
Apr 10, 2012
Bought 11.4 K USD
Kapusta Matthew C
SVP, Business Development
+ 1000
11.397 USD
12 years ago
Apr 09, 2012
Bought 23.6 K USD
BUCCI VINCENT
Director
+ 2000
11.798 USD
12 years ago
Feb 21, 2012
Bought 26.9 K USD
BUCCI VINCENT
Director
+ 2000
13.439 USD
12 years ago
Feb 15, 2012
Bought 26.5 K USD
BUCCI VINCENT
Director
+ 2000
13.2469 USD
12 years ago
Feb 13, 2012
Bought 12.9 K USD
BUCCI VINCENT
Director
+ 1000
12.9269 USD
12 years ago
Feb 13, 2012
Bought 38.8 K USD
DEVIVO JOSEPH
President and CEO
+ 3000
12.95 USD
13 years ago
Nov 16, 2011
Bought 35.4 K USD
DEVIVO JOSEPH
President and CEO
+ 2500
14.145 USD
13 years ago
Aug 16, 2011
Bought 37.8 K USD
BUCCI VINCENT
Director
+ 2700
14.01 USD
13 years ago
Aug 16, 2011
Bought 42.3 K USD
BUCCI VINCENT
Director
+ 3000
14.11 USD
13 years ago
Aug 16, 2011
Bought 1.4 K USD
BUCCI VINCENT
Director
+ 100
14 USD
13 years ago
Aug 16, 2011
Bought 2.8 K USD
BUCCI VINCENT
Director
+ 200
13.99 USD
14 years ago
Oct 19, 2010
Bought 7.14 K USD
LaPorte Steve
Director
+ 500
14.286 USD
14 years ago
Oct 19, 2010
Bought 7.14 K USD
LaPorte Steve
Director
+ 500
14.286 USD
14 years ago
Jul 20, 2010
Bought 7.35 K USD
LaPorte Steve
Director
+ 500
14.694 USD
14 years ago
Apr 07, 2010
Bought 7.76 K USD
LaPorte Steve
Director
+ 500
15.52 USD
14 years ago
Feb 12, 2010
Bought 8.18 K USD
LaPorte Steve
Director
+ 500
16.354 USD
14 years ago
Feb 05, 2010
Bought 63.2 K USD
JOHNSON WESLEY
Director
+ 4000
15.81 USD
15 years ago
Jul 22, 2009
Bought 22.8 K USD
LaPorte Steve
Director
+ 2000
11.4234 USD
15 years ago
Jul 22, 2009
Bought 23 K USD
DONNELLY HOWARD W
Director
+ 2000
11.5 USD
15 years ago
Jul 21, 2009
Bought 56.2 K USD
Keltjens Jan
President & CEO
+ 5000
11.25 USD
15 years ago
Apr 17, 2009
Bought 24 K USD
Orsatti Charles Thomas
Director
+ 2000
12 USD
16 years ago
Jan 19, 2009
Bought 0 USD
Keltjens Jan
President & CEO
+ 90000
0 USD
15 years ago
Apr 09, 2009
Bought 62.3 K USD
Keltjens Jan
President & CEO
+ 5000
12.4662 USD
15 years ago
Feb 11, 2009
Bought 65 K USD
Keltjens Jan
President & CEO
+ 5000
13 USD
15 years ago
Feb 13, 2009
Sell 195 K USD
HOBBS EAMONN P
President & CEO
- 15000
12.985 USD
16 years ago
Jan 27, 2009
Bought 33.7 K USD
JOHNSON WESLEY
Director
+ 2426
13.89 USD
16 years ago
Jan 23, 2009
Bought 35.5 K USD
DONNELLY HOWARD W
Director
+ 3000
11.8377 USD
16 years ago
Jan 09, 2009
Bought 12 K USD
LaPorte Steve
Director
+ 1000
12 USD
16 years ago
Jan 09, 2009
Bought 12 K USD
LaPorte Steve
Director
+ 1000
12 USD
16 years ago
Aug 05, 2008
Bought 15.9 K USD
LaPorte Steve
Director
+ 1000
15.92 USD
16 years ago
May 15, 2008
Bought 19.7 K USD
LaPorte Steve
Director
+ 1300
15.128 USD
16 years ago
Apr 16, 2008
Bought 35.2 K USD
HOBBS EAMONN P
President & CEO
+ 2715
12.9671 USD
17 years ago
Aug 09, 2007
Sell 105 K USD
Shea Paul J
VP - Sales
- 5100
20.6388 USD
18 years ago
Jan 16, 2007
Sell 86.4 K USD
RECINELLA DANIEL
VP - Product Development
- 3455
25 USD
18 years ago
Nov 28, 2006
Sell 59.3 K USD
Stern Linda B
10 percent owner
- 2750
21.5474 USD
18 years ago
Nov 17, 2006
Sell 58.2 K USD
Stern Linda B
10 percent owner
- 2750
21.15 USD
18 years ago
Nov 13, 2006
Sell 55.5 K USD
Stern Linda B
10 percent owner
- 2750
20.1918 USD
18 years ago
Nov 09, 2006
Sell 57.4 K USD
Stern Linda B
10 percent owner
- 2750
20.8692 USD
18 years ago
Oct 24, 2006
Sell 63.1 K USD
Stern Linda B
10 percent owner
- 2750
22.9345 USD
18 years ago
Oct 17, 2006
Sell 64.8 K USD
Stern Linda B
10 percent owner
- 2750
23.5616 USD
18 years ago
Oct 09, 2006
Sell 62.9 K USD
Stern Linda B
10 percent owner
- 2750
22.8864 USD
18 years ago
Oct 03, 2006
Sell 57.8 K USD
Stern Linda B
10 percent owner
- 2750
21.0217 USD
18 years ago
Sep 26, 2006
Sell 58.6 K USD
Stern Linda B
10 percent owner
- 2750
21.3152 USD
18 years ago
Sep 22, 2006
Sell 50.3 K USD
Stern Linda B
10 percent owner
- 2750
18.2769 USD
18 years ago
Sep 20, 2006
Sell 50.3 K USD
Stern Linda B
10 percent owner
- 2750
18.2764 USD
18 years ago
Sep 13, 2006
Sell 44.4 K USD
Stern Linda B
10 percent owner
- 2750
16.1361 USD
18 years ago
Aug 24, 2006
Sell 46.7 K USD
Stern Linda B
10 percent owner
- 2750
16.9893 USD
18 years ago
Aug 16, 2006
Sell 50.3 K USD
Stern Linda B
10 percent owner
- 2750
18.2927 USD
18 years ago
Aug 10, 2006
Sell 59.9 K USD
Stern Linda B
10 percent owner
- 2750
21.7722 USD
18 years ago
Aug 07, 2006
Sell 65.8 K USD
Stern Linda B
10 percent owner
- 2750
23.9418 USD
18 years ago
Jul 28, 2006
Sell 87.9 K USD
Stern Linda B
10 percent owner
- 3750
23.4269 USD
18 years ago
Jul 24, 2006
Sell 90.3 K USD
Stern Linda B
10 percent owner
- 3750
24.0725 USD
18 years ago
Jul 20, 2006
Sell 91.2 K USD
Stern Linda B
10 percent owner
- 3750
24.3118 USD
18 years ago
Jul 18, 2006
Sell 90 K USD
Stern Linda B
10 percent owner
- 3750
23.9914 USD
18 years ago
Jul 17, 2006
Sell 91 K USD
Stern Linda B
10 percent owner
- 3750
24.263 USD
18 years ago
Jul 11, 2006
Sell 97.2 K USD
Stern Linda B
10 percent owner
- 3750
25.9223 USD
18 years ago
Jul 07, 2006
Sell 99.8 K USD
Stern Linda B
10 percent owner
- 3750
26.6249 USD
18 years ago
Jul 03, 2006
Sell 101 K USD
Stern Linda B
10 percent owner
- 3750
26.8736 USD
18 years ago
Jun 23, 2006
Sell 20.3 K USD
Stern Linda B
10 percent owner
- 781
25.998 USD
18 years ago
May 25, 2006
Sell 20.3 K USD
Stern Linda B
10 percent owner
- 781
25.9472 USD
18 years ago
May 01, 2006
Sell 134 K USD
GERARDI JOSEPH G
Vice President - CFO
- 4500
29.84 USD
18 years ago
Apr 03, 2006
Sell 43.2 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1500
28.8 USD
18 years ago
Apr 03, 2006
Sell 71.6 K USD
GERARDI JOSEPH G
Vice President - CFO
- 2500
28.64 USD
18 years ago
Apr 03, 2006
Sell 29 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
29 USD
18 years ago
Mar 22, 2006
Sell 70.4 K USD
GERARDI JOSEPH G
Vice President - CFO
- 2500
28.17 USD
18 years ago
Mar 01, 2006
Sell 37.4 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1500
24.932 USD
18 years ago
Mar 01, 2006
Sell 25 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
25.02 USD
19 years ago
Feb 01, 2006
Sell 136 K USD
GERARDI JOSEPH G
Vice President - CFO
- 5000
27.2 USD
19 years ago
Feb 01, 2006
Sell 108 K USD
APPLING WILLIAM M
Vice-President - Research
- 4000
27.0125 USD
19 years ago
Jan 10, 2006
Sell 67.5 K USD
GERARDI JOSEPH G
Vice President - CFO
- 2500
27 USD
19 years ago
Jan 06, 2006
Sell 134 K USD
APPLING WILLIAM M
Vice-President - Research
- 5000
26.75 USD
19 years ago
Jan 03, 2006
Sell 50.6 K USD
GERARDI JOSEPH G
Vice President - CFO
- 2000
25.325 USD
19 years ago
Jan 03, 2006
Sell 50.7 K USD
APPLING WILLIAM M
Vice-President - Research
- 2000
25.3625 USD
19 years ago
Jan 03, 2006
Sell 75.3 K USD
APPLING WILLIAM M
Vice-President - Research
- 3000
25.1083 USD
19 years ago
Dec 28, 2005
Sell 40.6 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
24.981 USD
19 years ago
Dec 21, 2005
Sell 39.4 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
24.25 USD
19 years ago
Dec 14, 2005
Sell 39.3 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
24.23 USD
19 years ago
Dec 14, 2005
Sell 50.5 K USD
APPLING WILLIAM M
Vice-President - Research
- 2000
25.25 USD
19 years ago
Dec 15, 2005
Sell 134 K USD
APPLING WILLIAM M
Vice-President - Research
- 5000
26.75 USD
19 years ago
Dec 07, 2005
Sell 36 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1500
24 USD
19 years ago
Dec 06, 2005
Sell 46 K USD
APPLING WILLIAM M
Vice-President - Research
- 2000
23 USD
19 years ago
Dec 07, 2005
Sell 37.2 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
22.92 USD
19 years ago
Nov 30, 2005
Sell 32 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
19.7 USD
19 years ago
Dec 01, 2005
Sell 20.6 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
20.62 USD
19 years ago
Dec 01, 2005
Sell 21.5 K USD
APPLING WILLIAM M
Vice-President - Research
- 1000
21.5 USD
19 years ago
Nov 23, 2005
Sell 32.4 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
19.97 USD
19 years ago
Nov 16, 2005
Sell 32.2 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
19.85 USD
19 years ago
Nov 09, 2005
Sell 35.9 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
22.08 USD
19 years ago
Nov 02, 2005
Sell 37.7 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
23.22 USD
19 years ago
Nov 01, 2005
Sell 21.5 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
21.5 USD
19 years ago
Nov 01, 2005
Sell 46 K USD
APPLING WILLIAM M
Vice-President - Research
- 2000
23 USD
19 years ago
Nov 01, 2005
Sell 21.5 K USD
APPLING WILLIAM M
Vice-President - Research
- 1000
21.5 USD
19 years ago
Oct 26, 2005
Sell 36.8 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
22.63 USD
19 years ago
Oct 21, 2005
Sell 21.5 K USD
APPLING WILLIAM M
Vice-President - Research
- 1000
21.5 USD
19 years ago
Oct 19, 2005
Sell 34.5 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
21.23 USD
19 years ago
Oct 12, 2005
Sell 31.9 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
19.67 USD
19 years ago
Oct 05, 2005
Sell 31.7 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
19.55 USD
19 years ago
Oct 03, 2005
Sell 20.7 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
20.67 USD
19 years ago
Sep 27, 2005
Sell 36.1 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1500
24.08 USD
19 years ago
Sep 28, 2005
Sell 37.4 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
23.02 USD
19 years ago
Sep 21, 2005
Sell 35.7 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
22.01 USD
19 years ago
Sep 14, 2005
Sell 36.6 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
22.51 USD
19 years ago
Sep 07, 2005
Sell 36.8 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
22.69 USD
19 years ago
Sep 01, 2005
Sell 21 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
20.95 USD
19 years ago
Aug 31, 2005
Sell 34.4 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
21.16 USD
19 years ago
Aug 24, 2005
Sell 35.1 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
21.594 USD
19 years ago
Aug 17, 2005
Sell 37.5 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
23.1 USD
19 years ago
Aug 10, 2005
Sell 37.1 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
22.84 USD
19 years ago
Aug 04, 2005
Sell 36 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1500
24 USD
19 years ago
Aug 03, 2005
Sell 38.3 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
23.58 USD
19 years ago
Aug 01, 2005
Sell 23.1 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
23.101 USD
19 years ago
Jul 27, 2005
Sell 35.3 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
21.75 USD
19 years ago
Jul 20, 2005
Sell 40.2 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
24.78 USD
19 years ago
Jul 13, 2005
Sell 39.8 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
24.49 USD
19 years ago
Jul 11, 2005
Sell 125 K USD
RECINELLA DANIEL
VP - Product Development
- 5000
25 USD
19 years ago
Jul 11, 2005
Sell 36.4 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1500
24.28 USD
19 years ago
Jul 11, 2005
Sell 194 K USD
APPLING WILLIAM M
Vice-President - Research
- 8000
24.28 USD
19 years ago
Jul 06, 2005
Sell 34.3 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
21.15 USD
19 years ago
Jul 01, 2005
Sell 21.1 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
21.1366 USD
19 years ago
Jun 29, 2005
Sell 35.3 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
21.73 USD
19 years ago
Jun 22, 2005
Sell 34.9 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
21.51 USD
19 years ago
Jun 16, 2005
Sell 21 K USD
APPLING WILLIAM M
Vice-President - Research
- 1000
21 USD
19 years ago
Jun 08, 2005
Sell 33.6 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
20.7 USD
19 years ago
Jun 06, 2005
Sell 42.7 K USD
APPLING WILLIAM M
Vice-President - Research
- 2000
21.35 USD
19 years ago
Jun 01, 2005
Sell 7.81 K USD
GERARDI JOSEPH G
Vice President - CFO
- 409
19.091 USD
19 years ago
Jun 01, 2005
Sell 11.2 K USD
GERARDI JOSEPH G
Vice President - CFO
- 591
19 USD
19 years ago
Jun 01, 2005
Sell 31.7 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
19.5 USD
19 years ago
May 25, 2005
Sell 31.4 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
19.313 USD
19 years ago
May 18, 2005
Sell 29.7 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
18.27 USD
19 years ago
May 11, 2005
Sell 30 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
18.5 USD
19 years ago
May 04, 2005
Sell 28.3 K USD
STERN HOWARD S
director, 10 percent owner:
- 1624
17.4033 USD
19 years ago
Apr 06, 2005
Sell 359 K USD
GOLD JEFFREY
Director
- 20000
17.9253 USD
19 years ago
May 03, 2005
Sell 18 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
18.0078 USD
19 years ago
Apr 01, 2005
Sell 18.3 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
18.27 USD
19 years ago
Mar 21, 2005
Sell 21 K USD
APPLING WILLIAM M
Vice-President - Research
- 1000
21 USD
19 years ago
Mar 01, 2005
Sell 44.1 K USD
RECINELLA DANIEL
VP - Product Development
- 2000
22.0301 USD
19 years ago
Mar 01, 2005
Sell 22 K USD
GERARDI JOSEPH G
Vice President - CFO
- 1000
22.0301 USD
20 years ago
Feb 04, 2005
Sell 83.4 K USD
APPLING WILLIAM M
Vice-President - Research
- 4100
20.3378 USD
19 years ago
Feb 07, 2005
Sell 80.4 K USD
APPLING WILLIAM M
Vice-President - Research
- 3873
20.75 USD
20 years ago
Feb 04, 2005
Sell 83.4 K USD
GERARDI JOSEPH G
Vice President - CFO
- 4100
20.3378 USD
19 years ago
Feb 07, 2005
Sell 80.4 K USD
GERARDI JOSEPH G
Vice President - CFO
- 3873
20.75 USD
20 years ago
Feb 02, 2005
Sell 82.4 K USD
GERARDI JOSEPH G
Vice President - CFO
- 4000
20.6043 USD
20 years ago
Feb 03, 2005
Sell 6.16 K USD
GERARDI JOSEPH G
Vice President - CFO
- 300
20.5233 USD
20 years ago
Feb 02, 2005
Sell 82.4 K USD
APPLING WILLIAM M
Vice-President - Research
- 4000
20.6043 USD
20 years ago
Feb 03, 2005
Sell 6.16 K USD
APPLING WILLIAM M
Vice-President - Research
- 300
20.5233 USD
20 years ago
May 27, 2004
Bought 13.2 K USD
FLAHERTY ROBERT E
Director
+ 1200
11 USD
20 years ago
May 27, 2004
Bought 5.5 K USD
Casciaro Gregory D
Director
+ 500
11 USD
20 years ago
Oct 15, 2004
Sell 58.9 K USD
STERN HOWARD S
Director
- 6851
8.6 USD
20 years ago
May 27, 2004
Bought 13.2 K USD
FLAHERTY ROBERT E
Director
+ 1200
11 USD
20 years ago
May 27, 2004
Bought 5.5 K USD
Casciaro Gregory D
Director
+ 500
11 USD
7. News
AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential. seekingalpha.com - 2 weeks ago
AngioDynamics price target raised to $15 from $12 at Canaccord Canaccord raised the firm's price target on AngioDynamics to $15 from $12 and keeps a Buy rating on the shares. AngioDynamics reported one of its strongest quarters in recent memory, the analyst tells investors in a research note. The firm back-end loaded its NanoKnife expectations for this fiscal year, but thinks in the long-term it could provide significant growth for AngioDynamics. It sees thrombectomy acceleration today with improving profitability. https://thefly.com - 3 weeks ago
AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business. zacks.com - 3 weeks ago
AngioDynamics: A Surgical Approach To Market Growth AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue. seekingalpha.com - 3 weeks ago
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript AngioDynamics, Inc. (NASDAQ:ANGO ) Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call. seekingalpha.com - 3 weeks ago
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. zacks.com - 3 weeks ago
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights   Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sa. businesswire.com - 3 weeks ago
AngioDynamics to Present at the J.P. Morgan Healthcare Conference LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at 7:30. businesswire.com - 3 weeks ago
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Confer. businesswire.com - 3 weeks ago
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarte. businesswire.com - 1 month ago
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes. zacks.com - 1 month ago
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength? AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 1 month ago
8. Profile Summary

AngioDynamics, Inc. ANGO

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 478 M
Dividend Yield 0.00%
Description AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Contact 14 Plaza Drive, Latham, NY, 12110 https://www.angiodynamics.com
IPO Date June 1, 2004
Employees 748
Officers Mr. Saleem M. Cheeks Vice President of Communications Mr. Benjamin H. Davis Senior Vice President of Business Development & Strategy Ms. Kim L. Seabury Senior Vice President of Information Technology Mr. Warren G. Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain Mr. Juan Carlos Serna Senior Vice President of Scientific & Clinical Affairs Ms. Marna I. Bronfen-Moore Senior Vice President of Human Resources Mr. Stephen A. Trowbridge Executive Vice President & Chief Financial Officer Mr. James C. Clemmer Chief Executive Officer, President & Director